Bioporto AS (OCSE:BIOPOR) Other Stockholders Equity: kr1.22 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:BIOPOR Bioporto AS OCSE:BIOPOR
71 GF Score
Price kr1.18
GF Value kr1.23
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Bioporto AS Other Stockholders Equity?

Bioporto AS OCSE:BIOPOR -2.49% 71 Other Stockholders Equity is kr1.22 Mil as of Dec. 2025. GuruFocus rates OCSE:BIOPOR with a GF Score™ of 71/100 and a GF Value™ of kr1.23 (Fairly Valued). The stock has 3 warning signs investors should review.

Bioporto AS's Other Stockholders Equity for the quarter that ended in Dec. 2025 was kr1.22 Mil.

Bioporto AS's quarterly Other Stockholders Equity increased from Jun. 2025 (kr1.60 Mil) to Sep. 2025 (kr1.76 Mil) but then declined from Sep. 2025 (kr1.76 Mil) to Dec. 2025 (kr1.22 Mil).

Bioporto AS's annual Other Stockholders Equity declined from Dec. 2023 (kr0.22 Mil) to Dec. 2024 (kr-1.05 Mil) but then increased from Dec. 2024 (kr-1.05 Mil) to Dec. 2025 (kr1.22 Mil).

Bioporto AS Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Bioporto AS's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bioporto AS Other Stockholders Equity Chart

Bioporto AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.12 -0.23 0.22 -1.05 1.22

Bioporto AS Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.05 -0.35 1.60 1.76 1.22
OCSE:BIOPOR
71GF Score
Bioporto AS OCSE:BIOPOR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bioporto AS Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of kr1.22 Mil mean?
Bioporto AS (OCSE:BIOPOR) has a Other Stockholders Equity of kr1.22 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bioporto AS and its competitors.
Is Bioporto AS's Other Stockholders Equity too high?
Bioporto AS's current Other Stockholders Equity is kr1.22 Mil. Overall, Bioporto AS has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Other Stockholders Equity compare to TMO and DHR?
Bioporto AS's Other Stockholders Equity of kr1.22 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Bioporto AS and its competitors. Bioporto AS's current Other Stockholders Equity is kr1.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Based on GuruFocus' analysis, Bioporto AS (OCSE:BIOPOR) is currently considered Fairly Valued. The stock's GF Value™ is kr1.23, compared to a current price of kr1.18 — trading 4.5% below its estimated fair value. The current Other Stockholders Equity is kr1.22 Mil. Bioporto AS's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Bioporto AS (OCSE:BIOPOR), the current Other Stockholders Equity is kr1.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bioporto AS (OCSE:BIOPOR) Overvalued in 2026?

Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued. The current stock price of kr1.18 is trading 4.5% below its estimated GF Value™ of kr1.23. GuruFocus considers Bioporto AS to be Fairly Valued.

Key valuation signals for OCSE:BIOPOR:

  • Other Stockholders Equity: kr1.22 Mil
  • GF Value™: kr1.23 vs. price of kr1.18 (4.5% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the OCSE:BIOPOR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioporto AS Business Description

Other Exchanges 0JJM:UK
Address Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
71GF Score

Get the complete analysis for OCSE:BIOPOR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.18
Price
kr1.23
GF Value